IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Rick Costantino who wrote (1092)	7/8/1997 9:51:00 PM
From: DZOO	of 1762

I think the quote has some validity from an analyst's point of view. Especially since it was aimed at the general public. I think he was trying to emphasize the level of scrutiny and risk involved. As you probably know, if approved this will be just the first of several competing monoclonal antibody products. I have a problem with the quote because it implies that the subsequent monoclonals will not be scrutinized as rigorously. I don't think that is true and I think that is misleading to the general public. The risk of monetary loss is quite high and the risk should be emphasized. If Rituxan is disapproved IMO IDPH's stock price will fall to the single digits. If approved the skys the limit given the projected billion dollar market. Well maybe not the sky but $60 / sh would be close enough for me, long term that is.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next